I have covered two bankruptcy stories before. Not from the usual angle of what happened and why; for each, I dug deeper into who could win from the wreckage.
The Magellan Aerospace story led me to Howmet. The IKEA store closures pointed me to Target. This week’s Chapter 11 filing from Focus Factor maker Synergy CHC Corp. points me squarely to Reckitt Benckiser (RBGLY).
Synergy CHC filed for bankruptcy on September 4, 2026, in the U.S. Bankruptcy Court for the District of Columbia, TheStreet reported.
Costco told the company back in July that it would be discontinuing Focus Factor products after a 16-year relationship. You see that one decision? It cost Synergy approximately 58% of its total 2025 net revenue, triggered an $18.9 million debt acceleration from its lender, and made Chapter 11 inevitable.
RBGLY currently trades at $14, down 10.62% year-to-date, according to Yahoo Finance.
How a 58% revenue concentration becomes a fatal single point of failure
The Synergy CHC situation shows just how quickly retail concentration can become a risk. Focus Factor is a functional beverage brand with a 25-year legacy, enjoying established distribution in the U.S., Canada, and Mexico, and distribution across Walmart, Walgreens, Amazon, and BJ’s.
The company’s a brain supplement with vitamins, minerals, and neuro-nutrients. It carries a “#1 Pharmacist Recommended” claim from the 2025-2026 U.S. Pharmacy Times survey for memory support. None of that mattered once Costco made its decision.
More Retail:
“Costco accounted for approximately 58% of the Company’s net revenue during the fiscal year ended December 31, 2025,” the SEC filing stated. “The Company expects Costco’s decision to have a material adverse effect on the Company’s business, results of operations, liquidity, and financial condition.”
Costco did not give a public reason for dropping the brand. It did not need to. It’s a retailer that moves products in bulk, and it made its vendor decision for whatever reason.
The $18.9 million debt acceleration that followed confirmed Synergy had no financial cushion to survive even a temporary revenue disruption of this magnitude.
Why I think Reckitt’s Neuriva is the obvious beneficiary
Three structural advantages make Reckitt the clearest winner.
-
Neuriva is already in Costco’s system. The Neuriva Brain Supplement Original (50 capsules) currently retails at Costco for $43.99. Reckitt does not need to win a vendor slot or navigate Costco’s notoriously demanding supplier requirements. It is already approved, integrated, and selling. Scaling volume within an existing supplier relationship is operationally easy.
-
Reckitt’s product portfolio fits neatly into where Costco wants to go. Costco members tend to gravitate toward premium wellness products backed by established brands and research. Reckitt has been aggressively expanding Neuriva, with products including Neuriva Plus, Neuriva Ultra, and Neuriva Memory 3D. I see these premium formulations align with Costco’s push toward higher-margin health solutions far better than the legacy Focus Factor lineup.
-
The regulatory history matters, too. Focus Factor has faced FTC settlements and consumer class-action lawsuits challenging its efficacy claims. Reckitt builds Neuriva’s marketing around clinically studied ingredients and GMO-free formulations.
